Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Bupivacaine from the National Medical Products Administration, which will enhance the company's product line and core competitiveness [1][4]. Group 1: Approval Information - The chemical raw material drug approved is Bupivacaine, with registration number Y20230001273 [1]. - The application for the drug was submitted in December 2023, accepted in January 2024, and recently approved [2]. Group 2: Product Application - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [3]. Group 3: Impact on the Company - The approval of Bupivacaine will enrich the company's product line and enhance its core competitiveness [4].

Core Viewpoint - Recently, the company announced that it has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Bupivacaine [2] Group 1 - The company is Zhejiang Anglikang Pharmaceutical Co., Ltd. [2] - The approved chemical raw material drug is Bupivacaine [2] - The announcement was made on the evening of November 17 [2]

Core Viewpoint - Anglikon has received approval from the National Medical Products Administration for its chemical raw material drug, Bupivacaine, which meets the registration requirements for pharmaceuticals [1] Group 1: Company Information - Anglikon announced the receipt of the approval notice for the marketing application of Bupivacaine [1] - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The drug Bupivacaine is a chemical raw material approved for marketing [1] - The approval is significant for clinical applications in local anesthesia and postoperative pain management [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has received the approval notification from the National Medical Products Administration for the marketing application of the chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The drug Bupivacaine is a chemical raw material approved for marketing [1] - The approval is significant for the company's product portfolio in the anesthetic market [1] - Bupivacaine is clinically used for local anesthesia and postoperative pain relief [1]

Core Viewpoint - The company Anglikon (002940.SZ) has received approval from the National Medical Products Administration (NMPA) for the marketing application of its chemical raw material drug, Bupivacaine, which is primarily used for local anesthesia and postoperative analgesia [1] Group 1 - The approval notification was issued by the NMPA, indicating regulatory compliance and readiness for market entry [1] - Bupivacaine is a significant product in the field of anesthesia, enhancing the company's portfolio in the pharmaceutical industry [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the chemical raw material drug Bupivacaine, enhancing its product line and core competitiveness [1] Summary by Relevant Categories Regulatory Approval - The company submitted the drug registration application for Bupivacaine in December 2023, which was accepted in January 2024, and has now received the approval notice [1] Product Information - Bupivacaine is primarily used for local anesthesia and postoperative analgesia, indicating its significance in clinical applications [1] Strategic Implications - The approval of Bupivacaine will further enrich the company's product portfolio, thereby improving its competitive edge in the market [1]

Core Insights - The company Anglikon (002940) has received approval from the National Medical Products Administration for the marketing application of Bupivacaine [1] Group 1 - Bupivacaine is primarily used in clinical settings for local anesthesia and postoperative analgesia [1]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to achieve an EPS of 1.06/1.17 CNY for 2025-26, with a new forecast of 1.42 CNY for 2027. The target price is set at 56.18 CNY based on a PE ratio of 53 for 2025 [2] - The company reported a significant revenue increase of 22.63% year-on-year for 2024, reaching 27.985 billion CNY, and a net profit increase of 47.28%, totaling 6.337 billion CNY [9] - The company is actively advancing its internationalization efforts, with several products receiving FDA approval and significant licensing agreements contributing to revenue growth [9] Financial Information Summary - Revenue (in million CNY): - 2023A: 22,820 - 2024A: 27,985 (22.6% YoY growth) - 2025E: 31,684 (13.2% YoY growth) - 2026E: 35,553 (12.2% YoY growth) - 2027E: 40,900 (15.0% YoY growth) [4] - Net Profit (in million CNY): - 2023A: 4,302 - 2024A: 6,337 (47.3% YoY growth) - 2025E: 6,759 (6.7% YoY growth) - 2026E: 7,477 (10.6% YoY growth) - 2027E: 9,060 (21.2% YoY growth) [4] - EPS (in CNY): - 2023A: 0.67 - 2024A: 0.99 - 2025E: 1.06 - 2026E: 1.17 - 2027E: 1.42 [4] - Gross Margin: - 2023A: 84.6% - 2024A: 86.2% - 2025E: 84.5% - 2026E: 84.9% - 2027E: 85.4% [4] - Net Margin: - 2023A: 18.9% - 2024A: 22.6% - 2025E: 21.3% - 2026E: 21.0% - 2027E: 22.2% [4]

证券简称： 海昇药业 证券代码： 870656 浙江海昇药业股份有限公司 1-1-0 浙江省衢州市高新技术产业园区华阳路 36 号 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 浙江海昇药业股份有限公司招股说明书（申报稿） 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行后因发 行人经营与收益变化或者股票价格变动引致的投资风险。 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 1-1-1 声明 发行人及全体董事、监事、高级管理人员承诺招股说明书及其他信息披露资料不存在虚 假记载、误导性陈述或者重大遗漏，并对其真实性、准确性、完整性承担相应的法律责任。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资 ...